


Tactile Systems Technology Inc. (TCMD)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001027838

Tactile Systems Technology Inc.	
TCMD; healthcare	
Grade	  A strongest fifth of 371 graded peers percentile 4.1; sampling error 2.5 points; lower is stronger
Rank	16 of 371
Profitability	B  percentile 28.6
Solvency	A/B  percentile 21.4
Growth and financing	B/C  percentile 39.5
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$273.9M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: distress
Inputs computable	11 of 14
Graded from	filings received through Feb 17, 2026 234 days before the rescans; latest periodic filing 10-Q received Aug 10, 2026
Last close	\$22.11 2026-10-08; market equity \$500.8M
Price used in grade	None

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 17, 2026

Tactile Systems Technology, Inc. ("we," "us," and "our") is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation resulting in us being reincorporated as a Delaware corporation. The resulting

corporation assumed the name Tactile Systems Technology, Inc. and in September 2013, we began doing business as "Tactile Medical".

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 28.6						
Gross profitability		91.3%	32.2%	4.0	372	2025-12-31
Return on invested capital		not computable	9.3%			a prior annual debt, equity, and cash observation is required
Accruals ratio		(8.3%)	(6.6%)	47.0	811	2025-12-31
Gross margin stability, five years		1.9 pts	2.8 pts	34.7	243	2025-12-31
Solvency, sleeve percentile 21.4						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		8.52	(0.31)	11.1	756	2025-12-31
Net debt to EBITDA		(2.32x)	1.82x	8.1	75	2025-12-31
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		4.03x	2.96x	45.0	839	2025-12-31
Growth and financing, sleeve percentile 39.5						
Revenue growth, three-year compound		10.1%	10.0%	50.2	415	2025-12-31
Free cash flow growth, three-year compound		127.6%	10.9%	6.3	96	2025-12-31
Reinvestment rate		(94.8%)	37.1%	91.3	104	2025-12-31
Asset growth, three years		2.4%	2.1%	45.9	704	2025-12-31
Net share issuance, one year		(4.9%)	2.5%	3.6	634	2026-02-13


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 83,446,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
11	Castle Biosciences Inc. (CSTL)	2.7	A	fortress balance sheet
12	Penumbra Inc. (PEN)	3.0	A	
13	Lemaitre Vascular Inc. (LMAT)	3.2	A	
14	Corcept Therapeutics Inc. (CORT)	3.5	A	fortress balance sheet
15	Electromed, Inc. (ELMD)	3.8	A	fortress balance sheet
16	Tactile Systems Technology Inc. (TCMD) <	4.1	A	fortress balance sheet
17	Ideaya Biosciences, Inc. (IDYA)	4.3	A	
18	Vericel Corp. (VCEL)	4.6	A	
19	Tarsus Pharmaceuticals, Inc. (TARS)	4.9	A	fortress balance sheet
20	Biomarin Pharmaceutical Inc. (BMRN)	5.1	A	
21	Neurocrine Biosciences Inc. (NBIX)	5.4	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	66.0%	8.0%	81
Distance from 52-week high	(33.1%)	(31.4%)	46
EBIT to enterprise value	6.8%	(1.5%)	85
Free cash flow yield	8.1%	(1.0%)	88
Book value to price	0.45	0.28	66
Sales to price	0.66	0.31	74
Composite equity issuance, five years	14.9%	20.3%	45
Relative strength against the sector, log excess return	0.29	(0.14)	81

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$69.9M
Operating cash flow, four quarters	\$30.6M
Months of runway	not finite
Days since last periodic filing	60 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	\$6.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$250.1M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
2	assets	us-gaap:Assets	\$273.9M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
3	operating income	us-gaap:OperatingIncomeLoss	\$29.3M	2025-12-31	2026-02-17	10-K	0001104659-26-016380

4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItems	\$12.3M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-02-17	10-K	0001104659-26-016380
6	total debt	us-gaap:LongTermDebt	\$218.9M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
7	book equity	us-gaap:StockholdersEquity	\$83.4M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$19.1M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
9	net income	us-gaap:NetIncomeLoss	\$42.8M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$297.9M	2024-12-31	2026-02-17	10-K	0001104659-26-016380
11	assets	us-gaap:Assets	\$329.5M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$216.7M	2024-12-31	2026-02-17	10-K	0001104659-26-016380
13	gross profit	us-gaap:GrossProfit	\$293.0M	2024-12-31	2026-02-17	10-K	0001104659-26-016380
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$195.1M	2023-12-31	2026-02-17	10-K	0001104659-26-016380
15	gross profit	us-gaap:GrossProfit	\$274.4M	2023-12-31	2026-02-17	10-K	0001104659-26-016380
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$176.0M	2022-12-31	2025-02-18	10-K	0001558370-25-001096
17	gross profit	us-gaap:GrossProfit	\$246.8M	2022-12-31	2025-02-18	10-K	0001558370-25-001096
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$148.2M	2021-12-31	2024-02-20	10-K	0001558370-24-001330
19	gross profit	us-gaap:GrossProfit	\$208.1M	2021-12-31	2024-02-20	10-K	0001558370-24-001330
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$165.2M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
21	current assets	us-gaap:AssetsCurrent	\$41.0M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
22	current liabilities	us-gaap:LiabilitiesCurrent	\$54.9M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$55.0M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
24	liabilities	us-gaap:Liabilities	\$6.6M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$2.4M	2025-12-31	2026-02-17	10-K	0001104659-26-016380
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$40.7M	2024-12-31	2026-02-17	10-K	0001104659-26-016380
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.4M	2024-12-31	2026-02-17	10-K	0001104659-26-016380
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$35.9M	2023-12-31	2026-02-17	10-K	0001104659-26-016380
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.3M	2023-12-31	2026-02-17	10-K	0001104659-26-016380
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5.2M	2022-12-31	2025-02-18	10-K	0001558370-25-001096
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.8M	2022-12-31	2025-02-18	10-K	0001558370-25-001096
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$177.6M	2024-12-31	2026-02-17	10-K	0001104659-26-016380
33	current assets	us-gaap:AssetsCurrent	\$40.7M	2024-12-31	2026-02-17	10-K	0001104659-26-016380
34	current liabilities	us-gaap:LiabilitiesCurrent	\$281.4M	2023-12-31	2025-02-18	10-K	0001558370-25-001096
35	assets	us-gaap:Assets	\$255.0M	2022-12-31	2024-02-20	10-K	0001558370-24-001330
36	assets	us-gaap:Assets	22,438,926	2026-02-13	2026-02-17	10-K	0001104659-26-016380
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	23,585,175	2025-02-14	2025-02-18	10-K	0001558370-25-001096
38	shares outstanding	dei:EntityCommonStockSharesOutstanding					